Q2's headline beat was driven by low-margin logistics and pricing, not by more organs moving through the platform; service outgrew product by 16.4 pp. Revenue is increasingly concentrated in the liver ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Shares of TransMedics Group (TMDX-3.26%) recently bounded higher in response to a first-quarter earnings report that was a lot better than investors were expecting. Downward revenue guidance revisions ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Written by Jonathan Reid, Senior MedTech & Biotech Markets Editor. Jonathan focuses on fast-growing specialist healthcare names where clinical data, regulation and capital markets sentiment intersect, ...

From the beginning of 2024 through Aug. 23, shares of TransMedics (NASDAQ: TMDX) stock soared by 123% -- but the good times didn't last. A third-quarter earnings miss sent shares of the ...

TransMedics is a market-changing player in organ transplant technology, with a unique multi-organ perfusion platform. Read ...

TransMedics Group (TMDX) has been experiencing robust demand for its technology and services, which has supported recent gains for the medical stock. Thursday's IBD 50 Stock To Watch is now eyeing a ...